佳兆业健康(00876.HK)中期股东应占溢利增长387%至537.9万港元
格隆汇8月23日丨佳兆业健康(00876.HK)公布,截至2019年6月30日止6个月,公司收益达1.19亿港元,期间股东应占溢利537.9万港元,同比增长387%;毛利率升至49.40%(2018年:48.05%);每股盈利0.11港仙。
该集团将持续与技术机构合作,以获得更稳定的劳动资源供应,同时实施自动化减少对劳动资源的依赖。得益于研发和技术的投入,政府补助、培训谘询等其他收入增至9,100,000港元(2018年:1,400,000港元)。期间的研究及开发支出增加至14,300,000港元(2018年:10,500,000港元)。
该集团已于2019年5月23日完成通过总代价人民币193,000,000元收购从事公共健康及医疗服务的业佳有限公司参与健康行业。该收购事项获落实完成,使得该集团将能渗进健康行业之前线,直接应对及识别病人的需要。此举亦将有助于健康行业的投资决定,同时为该集团建立市场声誉。该收购事项预期将为该本集团现有业务带来协同效应,相信该集团的义齿业务可凭藉共享于该项目中将予兴建的该医院的资源及声誉,进一步立足于长三角地区。
此外,该集团已于2019年五月成立深圳医佳健康医疗科技有限公司,已组建骨科、康复、疼痛全国级专家教授团队,与技术成熟的运动康复机构合作,在运动康复这个细分领域围绕运动的延伸产业链,顾客制定安全且专业的方案。该团队与深圳二院、人民医院、北大医院等近二十家医院深入合作。
公司称,集团主要从事义齿业务,其业务战略为透过加大扩展业务,以进一步提升股东价值。打造美加品牌,以先进技术为导向,融合国内、外优质医疗器械资源,成为高端义齿耗材供货商。该集团积极探索以口腔上下游为产业链的医疗器械体系,以医养、康养结合的医疗服务体系,三大体系相互协同,形成生态死循环。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.